Tradition Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Tradition Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$208K	Buy	67,738 +1,325	+2%	+$5.12K	0.01%	470
2025 Q4	$272K	Buy	66,413 +25,702	+63%	+$127K	0.02%	404
2025 Q3	$199K	Buy	+40,711	New	+$214K	0.01%	459
2024 Q1	–	Sell	-1,584	Closed	-$16K	–	1020
2023 Q4	$16K	Buy	1,584 +500	+46%	+$3.56K	﹤0.01%	902
2023 Q3	$8K	Buy	+1,084	New	+$10.8K	﹤0.01%	1071

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tradition Wealth Management's RXRX Position: Q1 2026 in Review

Tradition Wealth Management increased its Recursion Pharmaceuticals (RXRX) stake by 2% in Q1 2026, buying an estimated $5.12K and bringing the position to 67,738 shares worth $208K. The position accounts for 0.01% of the portfolio, ranked #470.

Tradition Wealth Management first reported a position in RXRX in Q3 2023 and has held it in 5 quarters since. The position peaked at $272K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Tradition Wealth Management held 67,738 shares of Recursion Pharmaceuticals worth $208K as of Q1 2026.
Tradition Wealth Management bought 1,325 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.12K.
Recursion Pharmaceuticals made up 0.01% of Tradition Wealth Management's portfolio in Q1 2026, its #470 holding.
Tradition Wealth Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 5 quarters since.
Tradition Wealth Management's Recursion Pharmaceuticals position peaked at $272K in Q4 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Tradition Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.